New Zealand

Home / Species & Products / Beef Cattle / Ultravac 5 in 1

Ultravac 5 in 1

Ultravac 5in1 is a multi-component adjuvant vaccine containing Clostridium perfringens type D, Clostridium tetani, Clostridium novyi type B, Clostridium septicum (as ultra filtered toxoids) and Clostridium chauvoei (as formol culture). The adjuvant, which is an aluminium salt, increases the level and duration of the immunity conferred by the vaccine. The type of adjuvant and the purification procedures used ensure maximum protection of stock with minimum risk of local reactions at the site of injection. Thiomersal 0.1mg/mL is added as a preservative.

Expand All
  • Approved uses/Indications

    Ultravac 5in1 is effective in the prevention of enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg-like disease) and blackleg in cattle and sheep, including swelled head in rams.

    This vaccine has been fully tested and found to conform to accepted standards of potency, safety and sterility.

  • Key Features

    Safe and efficacious in young lambs and calves: Ultravac 5in1 is effective in the presence of antibodies from colostrum (first milk) so cattle and sheep may be vaccinated at any age. This allows for early protection which minimises the risk of a potentially fatal immunity gap.

    Breakthrough technology: Ultravac 5in1 uses a unique ultrafiltration process to create a pure and concentrated vaccine that stimulates rapid and effective protection against the dangerous clostridial diseases.

    Low dose volume: Ultravac 5in1 has a 1 mL dose for sheep of all ages and a 2 mL dose for cattle of all ages. This means there’s less fridge space required for storage and fewer pack changes required when vaccinating large numbers of stock.

    Long lasting DOI: Ultravac 5in1 has a duration of immunity of at least 12 months against tetanus and blackleg.

  • Packaging

    Ultravac 5in1 is available in 100mL, 250mL and 500mL vials.

  • Dosage & Administration

    For subcutaneous use only. Inject high on neck behind ear.

    Cattle and sheep may be vaccinated at any age. Lambs are most conveniently vaccinated at marking time, and calves from six weeks of age onwards.

    Cattle including calves: 2 mL dose followed by a 2 mL booster 4 weeks later.

    A booster dose of 2 mL given 12 months after the two basic doses of vaccine should confer lifelong immunity against tetanus and blackleg. To maintain effective immunity against black disease, annual booster doses of Ultravac 5in1 should be given.

    The two basic doses of Ultravac 5in1 should provide effective immunity against enterotoxaemia for three months. Booster doses are therefore necessary to maintain immunity against enterotoxaemia (pulpy kidney disease) in cattle and should be given at appropriate intervals according to local and seasonal conditions.

    Sheep including lambs: 1 mL dose followed by a 1 mL booster 4 weeks later.

    A booster dose of 1 mL given 12 months after the two basic doses of vaccine should confer lifelong immunity against tetanus and blackleg, but may not do so against enterotoxaemia (pulpy kidney disease) or black disease. Further annual doses may be required to maintain effective immunity against these diseases in areas where the risks from the disease are known to be high.

    Pregnant ewes: If the ewes have not been previously vaccinated, a 1 mL dose should be given at the time of mating and a second dose of 1 mL should be given within four weeks of the expected date of lambing. If the ewes have been previously vaccinated, the dose at the time of mating may be omitted. Successfully vaccinated pregnant ewes will not only be protected themselves but will also pass on immunity to their lambs in the colostrum or ‘first milk’; such lambs should be protected for the first 6 to 8 weeks of their lives against these diseases.

    Development of immunity: Immunity develops about 10 days after vaccination. The second dose, given four weeks after the first should ensure a high level of immunity against the diseases covered by the vaccine.

    Withholding periods: Nil

  • Precautions

    Localised swelling may develop at the site of injection and a firm nodular lump may persist for some weeks.

    This vaccine has been fully tested for sterility and safety before issue but it must be stressed that the correct vaccination procedure in the field is equally important if secondary infection is to be prevented. Very occasionally pathogenic organisms lying dormant in the animal’s tissues are activated at the time of vaccination. This may lead to losses of stock but fortunately is of rare occurrence. As the above factors are beyond the control of the manufacturer except to the extent of any liability imposed by statute law without right of exclusion, Zoetis cannot accept responsibility for any disability or loss of stock following vaccination in respect of failure to use the correct vaccination procedure described on the label or disability or loss to any animal caused by the product.

    Store at 2–8°C (refrigerate; do not freeze). Shake well before use and keep thoroughly mixed during use. This product can be stored and used for up to 30 days after first opening. Handle aseptically and store refrigerated and protected from light. When not in use during any given vaccination session, keep the vaccine out of direct sunlight and as cool as possible. Do not leave exposed to light or at high temperatures for long periods. Ideally, place the vaccine pack into the original cardboard carton and place in either an esky with an icebrick or in a refrigerator.

  • Mandatories

    Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. ULTRAVAC is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A6935: RVM; Available only under Veterinary Authorisation. ACVM Registration No’s A3585: Unrestricted.

  • Contact Information

    For technical enquiries please phone Zoetis Technical Services on 0800 650 277.